Applied DNA Subsidiary, LineaRx Signs Joint Development Agreement with Takis and Evvivax

Applied DNA Sciences (NASDAQ:APDN) announced that LineaRx its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L. biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

As quoted in the press release:

Under the terms of the Agreement, LineaRx and Takis/Evvivax will jointly develop linear DNA expression vectors for two of Takis/Evvivax’s anti-cancer vaccine candidates utilizing LineaRx’s linear DNA technology. Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax vaccine candidates will be delivered to preclinical animal models via Takis/Evvivax’s proprietary electroporation technology. Antigen-specific immune responses aimed at achieving therapeutic effects will be studied.

The previously announced collaboration between the companies has already shown promise of yielding immunity in mice that were DNA-vaccinated against the human protein telomerase, which is over-expressed in more than 85% of all cancers.

Dr. Luigi Aurisicchio, CEO of Takis/Evvivax stated: “We are excited to co-develop linear DNA expression vectors for our DNA vaccine candidates with LineaRx. Initial data from the use of LineaRx’s amplicons in our vaccine candidates is promising. The advantages of linear DNA over plasmids would provide a clear market edge over plasmid-based DNA sources. We look forward to a mutually beneficial collaboration”.

Click here to read the full press release.